• Most Popular
  • Latest News
  • Breaking News
  • User Submitted Articles
  • Contribute an Article
  • GlobeNewswire
  • News and Analysis
  • About Us
  • Support
  • 10x Genomics to Present at the 36th Annual J.P. Morgan Healthcare Conference
    Wednesday, 03 January 2018 01:06
    Jan. 4, 2018 00:00 UTC

    10x Genomics to Present at the 36th Annual J.P. Morgan Healthcare Conference

    PLEASANTON, Calif.--(BUSINESS WIRE)-- 10x Genomics, Inc., a company focused on accelerating genomic discovery, announced that Serge Saxonov, Ph.D., co-founder and chief executive officer will present corporate and product updates during the 36th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 8, 2018 at 8:00 a.m. PT.

    “We are honored as a private company to have been selected for four consecutive years to present at the J.P. Morgan Healthcare Conference,” said Dr. Saxonov. “2017 has been a year of unprecedented growth for 10x Genomics. This will be a great opportunity to share in more detail how the company is impacting genomic discovery and the trajectory of our business.”

    About 10x Genomics

    10x Genomics is building tools for scientific discovery that reveal and address the true complexities of biology and disease. Through a combination of novel microfluidics, chemistry and

    bioinformatics, our award-winning ChromiumTM System is enabling researchers around the world to more fully understand the fundamentals of biology at unprecedented resolution and

    Error. Page cannot be displayed. Please contact your service provider for more details. (25)

    scale. Learn more at



    Media Contact
    Ryan Ferrell
    (312) 506-5202
    Investor Contact
    Matt Clawson
    Pure Communications
    (949) 370-8500

    Source: 10x Genomics

    BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

    Add this page to your favorite Social Bookmarking websites
    Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!


    BioMedReports #Arbutus’ LNP Licensee #Alnylam Announces #FDA Approval of ONPATTRO™ (patisiran), for the Treatment of ATTR Amyloid…
    BioMedReports Why CTI BioPharma Corp. Crashed Today